We are live on
!
Find out more
VF
Virtu Financial Portfolio holdings
AUM
$3.18B
Turnover
77.45%
1-Year Est. Return
65.92%
This Fund
S&P 500
This Quarter
Est. Return
+4.12%
1 Year Est. Return
+65.92%
3 Year Est. Return
+160.27%
5 Year Est. Return
+179.96%
10 Year Est. Return
–
AUM
$2.02B
AUM Growth
+$1.3B
(+180%)
Cap. Flow
+$1.27B
Cap. Flow
% of AUM
62.76%
Top 10 Holdings %
Top 10 Hldgs %
16.65%
Holding
2,553
New
2,160
Increased
164
Reduced
123
Closed
87
Avg Time Held Equity + Options
0.1
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.2
years
Avg Time Held Equity only
0.1
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck Gold Miners ETF
GDX
|
+$40.3M |
| 2 |
Berkshire Hathaway Class A
BRK.A
|
+$21M |
| 3 |
ProShares Short VIX Short-Term Futures ETF
SVXY
|
+$19.2M |
| 4 |
AF
Astoria Financial Corporation
AF
|
+$18.7M |
| 5 |
State Street DoubleLine Total Return Tactical ETF
TOTL
|
+$16.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$24.8M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$18.6M |
| 3 |
OKS
Oneok Partners LP
OKS
|
+$15.5M |
| 4 |
ProShares Short S&P500
SH
|
+$9.57M |
| 5 |
Invesco CurrencyShares British Pound Sterling Trust
FXB
|
+$7.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 57.39% |
| 2 | Financials | 7.24% |
| 3 | Consumer Discretionary | 7% |
| 4 | Healthcare | 6.56% |
| 5 | Technology | 4.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2126
Madison Covered Call & Equity Strategy Fund
MCN
$111M
| $79K | ﹤0.01% |
+10,093
| New | +$79K |
2017 Q3
0 quarters
|
|
2127
Theriva Biologics
TOVX
$9.54M
| $79K | ﹤0.01% |
+10
| New | +$57.8K |
2017 Q3
0 quarters
|
|
|
SPIL
2128
DELISTED
Siliconware Precision Industries Co Ltd
SPIL
| $79K | ﹤0.01% |
+10,031
| New | +$80K |
2017 Q3
0 quarters
|
|
2129
Arrowhead Research
ARWR
$7.9B
| $78K | ﹤0.01% |
+18,008
| New | +$42.9K |
2017 Q3
0 quarters
|
|
2130
Cemtrex
CETX
$2.96M
| – | – |
0
| – | – |
2017 Q3
0 quarters
|
|
|
BDSI
2131
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $78K | ﹤0.01% |
+26,601
| New | +$81K |
2017 Q3
0 quarters
|
|
2132
DELISTED
Catalyst Pharmaceutical
CPRX
| $77K | ﹤0.01% |
+30,372
| New | +$83.3K |
2017 Q3
0 quarters
|
|
2133
Comstock Resources
CRK
$4.11B
| $77K | ﹤0.01% |
+12,721
| New | +$82.7K |
2017 Q3
0 quarters
|
|
2134
Frontline
FRO
$11.7B
| $77K | ﹤0.01% |
+12,764
| New | +$72K |
2017 Q3
0 quarters
|
|
|
NMTR
2135
DELISTED
9 Meters Biopharma
NMTR
| $77K | ﹤0.01% |
+550
| New | +$86K |
2017 Q3
0 quarters
|
|
2136
eGain
EGAN
$145M
| $76K | ﹤0.01% |
+28,199
| New | +$54.9K |
2017 Q3
0 quarters
|
|
2137
Quantum Corp
QMCO
$728M
| $76K | ﹤0.01% |
+622
| New | +$83.4K |
2017 Q3
0 quarters
|
|
2138
CVR Partners
UAN
$1.34B
| $76K | ﹤0.01% |
+2,354
| New | +$77.2K |
2017 Q3
0 quarters
|
|
|
TTPH
2139
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $76K | ﹤0.01% |
+552
| New | +$73.8K |
2017 Q3
0 quarters
|
|
2140
GAMCO Global Gold, Natural Resources & Income Trust
GGN
$822M
| $75K | ﹤0.01% |
+13,437
| New | +$75K |
2017 Q3
0 quarters
|
|
2141
Franklin Master Intermediate Income Trust
PIM
$146M
| $75K | ﹤0.01% |
+15,864
| New | +$75K |
2017 Q3
0 quarters
|
|
|
TCON
2142
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $75K | ﹤0.01% |
+118
| New | +$61.5K |
2017 Q3
0 quarters
|
|
2143
DELISTED
Goldfield Corporation
GV
| $75K | ﹤0.01% |
+11,924
| New | +$60.7K |
2017 Q3
0 quarters
|
|
|
DNR
2144
DELISTED
Denbury Resources, Inc.
DNR
| $75K | ﹤0.01% |
55,964
+41,259
| +281% | +$53.8K |
2017 Q2
1 quarter
|
|
|
LBCC
2145
DELISTED
Long Blockchain Corp. Common Stock
LBCC
| $75K | ﹤0.01% |
+29,970
| New | +$116K |
2017 Q3
0 quarters
|
|
|
SRNE
2146
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $74K | ﹤0.01% |
43,348
+29,258
| +208% | +$53.7K |
2017 Q2
1 quarter
|
|
|
SPHS
2147
DELISTED
Sophiris Bio, Inc.
SPHS
| $74K | ﹤0.01% |
+34,671
| New | +$71.8K |
2017 Q3
0 quarters
|
|
2148
Alpha Pro Tech
APT
$56.6M
| $73K | ﹤0.01% |
+19,060
| New | +$65.6K |
2017 Q3
0 quarters
|
|
2149
Fate Therapeutics
FATE
$214M
| $73K | ﹤0.01% |
+18,493
| New | +$62.9K |
2017 Q3
0 quarters
|
|
2150
Tandem Diabetes Care
TNDM
$1.13B
| $73K | ﹤0.01% |
+9,957
| New | +$63K |
2017 Q3
0 quarters
|
|
Similar funds
GM
TA
CI
GIA
NSLI
Virtu Financial's Q3 2017 Portfolio in Review
As of Q3 2017, Virtu Financial held 2,553 positions worth $2.02B, up 180% from $721M the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Virtu Financial deployed $1.27B of net new capital in Q3 2017, opening 2,160 new positions and adding to 164 existing holdings. Its largest new stake was State Street DoubleLine Total Return Tactical ETF: 338,092 shares worth $16.7M.
By sector, the portfolio is most concentrated in Miscellaneous at 57% of assets, down from 79% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Vanguard S&P 500 ETF, an estimated $24.8M trimmed.
- Virtu Financial's largest Q3 2017 buy was State Street DoubleLine Total Return Tactical ETF: 338,092 shares worth $16.7M.
- Virtu Financial added most to VanEck Gold Miners ETF in Q3 2017, an estimated $40.3M increase.
- Virtu Financial's biggest Q3 2017 reduction was Vanguard S&P 500 ETF, cutting an estimated $24.8M.
- Virtu Financial fully exited Oneok Partners LP in Q3 2017, selling an estimated $15.5M.
- Virtu Financial's ten largest holdings make up 17% of its $2.02B portfolio in Q3 2017.
- Virtu Financial opened 2,160 new positions and closed 87 in Q3 2017.
- Virtu Financial's portfolio value rose 180% quarter-over-quarter to $2.02B.
Based on Virtu Financial's 13F filing for Q3 2017, filed 15 Nov 2017.